Prostanoid receptor EP2 as a therapeutic target

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4454-4465

  Ganesh, Thota ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 2 AGONIST; PROSTAGLANDIN E RECEPTOR 2 ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

BRAIN INJURY; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INDUCTION; EYE DISEASE; HEART DISEASE; HUMAN; INFLAMMATION; MICROGLIA; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; EYE DISEASES; GENE KNOCKOUT TECHNIQUES; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; STROKE;

EID: 84901264631     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401431x     Document Type: Review

References (125)

1. Lucas, S. M.; Rothwell, N. J.; Gibson, R. M. The role of inflammation in CNS injury and disease Br. J. Pharmacol. 2006, 147 (Suppl 1) S232-S240
2. Minghetti, L. Role of inflammation in neurodegenerative diseases Curr. Opin. Neurol. 2005, 18, 315-321 (Pubitemid 40813762)
3. Baumgart, D. C.; Carding, S. R. Gastroenterology 1-Inflammatory bowel disease: cause and immunobiology Lancet 2007, 369, 1627-1640 (Pubitemid 46722636)
4. McInnes, I. B.; Schett, G. The pathogenesis of rheumatoid arthritis N. Engl. J. Med. 2011, 365, 2205-2219
5. Sethi, S.; Mahler, D. A.; Marcus, P.; Owen, C. A.; Yawn, B.; Rennard, S. Inflammation in COPD: implications for management Am. J. Med. 2012, 125, 1162-1170
6. Tabas, I.; Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities Science 2013, 339, 166-172
7. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R. Inflammation and Alzheimer's disease Neurobiol. Aging 2000, 21, 383-421 (Pubitemid 30349107)
8. Heneka, M. T.; O'Banion, M. K. Inflammatory processes in Alzheimer's disease J. Neuroimmunol. 2007, 184, 69-91 (Pubitemid 46365992)
9. Ferrari, C. C.; Tarelli, R. Parkinson's disease and systemic inflammation Parkinsons Dis. 2011, 436813, 9 9 pp.
10. Przedborski, S. Inflammation and Parkinson's disease pathogenesis Mov. Disord. 2010, 25 (Suppl 1) S55-S57
11. Vezzani, A.; Aronica, E.; Mazarati, A.; Pittman, Q. J. Epilepsy and brain inflammation Exp. Neurol. 2013, 244, 11-21
12. Vezzani, A.; Balosso, S.; Ravizza, T. Inflammation and epilepsy Handb. Clin. Neurol. 2012, 107, 163-175
13. Vezzani, A.; French, J.; Bartfai, T.; Baram, T. Z. The role of inflammation in epilepsy Nature Rev. Neurol. 2011, 7, 31-40
14. Vezzani, A.; Friedman, A.; Dingledine, R. J. The role of inflammation in epileptogenesis Neuropharmacology 2013, 69, 16-24
15. McGeer, P. L.; McGeer, E. G. Inflammatory processes in amyotrophic lateral sclerosis Muscle Nerve 2002, 26, 459-470
16. Nagamoto-Combs, K.; McNeal, D. W.; Morecraft, R. J.; Combs, C. K. Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury J. Neurotrauma 2007, 24, 1719-1742 (Pubitemid 351267796)
17. Ramlackhansingh, A. F.; Brooks, D. J.; Greenwood, R. J.; Bose, S. K.; Turkheimer, F. E.; Kinnunen, K. M.; Gentleman, S.; Heckemann, R. A.; Gunanayagam, K.; Gelosa, G.; Sharp, D. J. Inflammation after trauma: microglial activation and traumatic brain injury Ann. Neurol. 2011, 70, 374-383
18. Turini, M. E.; DuBois, R. N. Cyclooxygenase-2: a therapeutic target Annu. Rev. Med. 2002, 53, 35-57 (Pubitemid 34177870)
19. Davies, N. M. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine Dis. Colon Rectum 1995, 38, 1311-1121
20. Murray, M. D.; Brater, D. C. Renal toxicity of the nonsteroidal anti-inflammatory drugs Annu. Rev. Pharmacol. Toxicol. 1993, 33, 435-465 (Pubitemid 23116014)
21. Knights, K. M.; Mangoni, A. A.; Miners, J. O. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity Expert Rev. Clin. Pharmacol. 2010, 3, 769-776
22. Anderson, G. D.; Hauser, S. D.; McGarity, K. L.; Bremer, M. E.; Isakson, P. C.; Gregory, S. A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis J. Clin. Invest. 1996, 97, 2672-2679 (Pubitemid 26187355)
23. Kang, R. Y.; Freire-Moar, J.; Sigal, E.; Chu, C. Q. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis Br. J. Rheumatol. 1996, 35, 711-718
24. DeWitt, D. L. Cox-2-selective inhibitors: the new super aspirins Mol. Pharmacol. 1999, 55, 625-631
25. Tacconelli, S.; Capone, M. L.; Sciulli, M. G.; Ricciotti, E.; Patrignani, P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity Curr. Med. Res. Opin. 2002, 18, 503-511 (Pubitemid 36133053)
26. Cannon, G. W.; Caldwell, J. R.; Holt, P.; McLean, B.; Seidenberg, B.; Bolognese, J.; Ehrich, E.; Mukhopadhyay, S.; Daniels, B. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group Arthritis Rheum. 2000, 43, 978-987 (Pubitemid 30368173)
27. Clemett, D.; Goa, K. L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain Drugs 2000, 59, 957-980 (Pubitemid 30232330)
28. Pasinetti, G. M.; Aisen, P. S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain Neuroscience 1998, 87, 319-324 (Pubitemid 28370892)
29. Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thal, L. J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA, J. Am. Med. Assoc. 2003, 289, 2819-2826 (Pubitemid 37430117)
30. Breitner, J. C.; Baker, L. D.; Montine, T. J.; Meinert, C. L.; Lyketsos, C. G.; Ashe, K. H.; Brandt, J.; Craft, S.; Evans, D. E.; Green, R. C.; Ismail, M. S.; Martin, B. K.; Mullan, M. J.; Sabbagh, M.; Tariot, P. N. Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimer's Dementia 2011, 7, 402-411
31. Grosser, T.; Yu, Y.; Fitzgerald, G. A. Emotion recollected in tranquility: lessons learned from the COX-2 saga Annu. Rev. Med. 2010, 61, 17-33
32. Egan, K. M.; Lawson, J. A.; Fries, S.; Koller, B.; Rader, D. J.; Smyth, E. M.; FitzGerald, G. A. COX-2-derived prostacyclin confers atheroprotection on female mice Science 2004, 306, 1954-1957 (Pubitemid 39627863)
33. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 2006, 116, 4-15 (Pubitemid 43121782)
34. Hirata, T.; Narumiya, S. Prostanoid receptors Chem. Rev. 2011, 111, 6209-6230
35. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: structures, properties, and functions Physiol. Rev. 1999, 79, 1193-1226 (Pubitemid 29473315)
36. Andreasson, K. Emerging roles of PGE2 receptors in models of neurological disease Prostaglandins Other Lipid Mediators 2010, 91, 104-112
37. Hata, A. N.; Breyer, R. M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacol. Ther. 2004, 103, 147-166 (Pubitemid 39209041)
38. Jones, R. L.; Giembycz, M. A.; Woodward, D. F. Prostanoid receptor antagonists: development strategies and therapeutic applications Br. J. Pharmacol. 2009, 158, 104-145
39. Dong, Y. J.; Jones, R. L.; Wilson, N. H. Prostaglandin-E Receptor Subtypes in Smooth-Muscle-Agonist Activities of Stable Prostacyclin Analogs Br. J. Pharmacol. 1986, 87, 97-107 (Pubitemid 16165892)
40. Bastien, L.; Sawyer, N.; Grygorczyk, R.; Metters, K. M.; Adam, M. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype J. Biol. Chem. 1994, 269, 11873-11877 (Pubitemid 24196675)
41. Liang, X.; Wang, Q.; Shi, J.; Lokteva, L.; Breyer, R. M.; Montine, T. J.; Andreasson, K. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis Ann. Neurol. 2008, 64, 304-314
42. McCullough, L.; Wu, L.; Haughey, N.; Liang, X.; Hand, T.; Wang, Q.; Breyer, R. M.; Andreasson, K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia J. Neurosci. 2004, 24, 257-268 (Pubitemid 38181690)
43. Gardiner, P. J. Characterization of Prostanoid Relaxant Inhibitory Receptors (Psi) Using a Highly Selective Agonist, TR4979 Br. J. Pharmacol. 1986, 87, 45-56 (Pubitemid 16134432)
44. Ahmad, A. S.; Zhuang, H. A.; Echeverria, V.; Dore, S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity J. Neurotrauma 2006, 23, 1895-1903 (Pubitemid 46034458)
45. Carrasco, E.; Werner, P.; Casper, D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress Neurosci. Lett. 2008, 441, 44-49
46. Jiang, J.; Ganesh, T.; Du, Y.; Thepchatri, P.; Rojas, A.; Lewis, I.; Kurtkaya, S.; Li, L.; Qui, M.; Serrano, G.; Shaw, R.; Sun, A.; Dingledine, R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 2307-2312
47. Liang, X.; Wang, Q.; Hand, T.; Wu, L.; Breyer, R. M.; Montine, T. J.; Andreasson, K. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease J. Neurosci. 2005, 25, 10180-10187 (Pubitemid 41636214)
48. Jin, J.; Shie, F. S.; Liu, J.; Wang, Y.; Davis, J.; Schantz, A. M.; Montine, K. S.; Montine, T. J.; Zhang, J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein J. Neuroinflammation 2007, 4, 2
49. Montine, T. J.; Milatovic, D.; Gupta, R. C.; Valyi-Nagy, T.; Morrow, J. D.; Breyer, R. M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent J. Neurochem 2002, 83, 463-70 (Pubitemid 35191411)
50. Shie, F. S.; Montine, K. S.; Breyer, R. M.; Montine, T. J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity Glia 2005, 52, 70-77 (Pubitemid 41532139)
51. Shie, F. S.; Breyer, R. M.; Montine, T. J. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity Am. J. Pathol. 2005, 166, 1163-1172 (Pubitemid 40524440)
52. Hoshino, T.; Nakaya, T.; Homan, T.; Tanaka, K.; Sugimoto, Y.; Araki, W.; Narita, M.; Narumiya, S.; Suzuki, T.; Mizushima, T. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo J. Biol. Chem. 2007, 282, 32676-32688 (Pubitemid 350159313)
53. Hsiao, H. Y.; Mak, O. T.; Yang, C. S.; Liu, Y. P.; Fang, K. M.; Tzeng, S. F. TNF-alpha/IFN-gamma-induced iNOS expression increased by prostaglandin E2 in rat primary astrocytes via EP2-evoked cAMP/PKA and intracellular calcium signaling Glia 2007, 55, 214-223
54. Banu, S. K.; Lee, J.; Speights, V. O., Jr.; Starzinski-Powitz, A.; Arosh, J. A. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms Mol. Endocrinol. 2009, 23, 1291-1305
55. Sheibanie, A. F.; Yen, J. H.; Khayrullina, T.; Emig, F.; Zhang, M.; Tuma, R.; Ganea, D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis J. Immunol. 2007, 178, 8138-8147 (Pubitemid 46898086)
56. Sung, Y. M.; He, G.; Hwang, D. H.; Fischer, S. M. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development Oncogene 2006, 25, 5507-5516 (Pubitemid 44344101)
57. Tani, K.; Naganawa, A.; Ishida, A.; Egashira, H.; Sagawa, K.; Harada, H.; Ogawa, M.; Maruyama, T.; Ohuchida, S.; Nakai, H.; Kondo, K.; Toda, M. Development of a highly selective EP2-receptor agonist. Part 2: Identification of 16-hydroxy-17,17-trimethylene 9beta-chloro PGF derivatives Bioorg. Med. Chem. 2002, 10, 1107-1114 (Pubitemid 34139925)
58. Mori, A.; Ishii, T.; Kuroki, T.; Shigeta, N.; Sakamoto, K.; Nakahara, T.; Ishii, K. The prostanoid EP(2) receptor agonist ONO-AE1-259-01 protects against glutamate-induced neurotoxicity in rat retina Eur. J. Pharmacol. 2009, 616, 64-67
59. Mori, A.; Saito, M.; Sakamoto, K.; Narita, M.; Nakahara, T.; Ishii, K. Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats Eur. J. Pharmacol. 2007, 570, 135-141 (Pubitemid 47248666)
60. Paralkar, V. M.; Borovecki, F.; Ke, H. Z.; Cameron, K. O.; Lefker, B.; Grasser, W. A.; Owen, T. A.; Li, M.; DaSilva-Jardine, P.; Zhou, M.; Dunn, R. L.; Dumont, F.; Korsmeyer, R.; Krasney, P.; Brown, T. A.; Plowchalk, D.; Vukicevic, S.; Thompson, D. D. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6736-6740 (Pubitemid 36666649)
61. Cameron, K. O.; Lefker, B. A.; Ke, H. Z.; Li, M.; Zawistoski, M. P.; Tjoa, C. M.; Wright, A. S.; DeNinno, S. L.; Paralkar, V. M.; Owen, T. A.; Yu, L.; Thompson, D. D. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation Bioorg. Med. Chem. Lett. 2009, 19, 2075-2078
62. Li, M.; Ke, H. Z.; Qi, H.; Healy, D. R.; Li, Y.; Crawford, D. T.; Paralkar, V. M.; Owen, T. A.; Cameron, K. O.; Lefker, B. A.; Brown, T. A.; Thompson, D. D. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing J. Bone. Miner. Res. 2003, 18, 2033-2042 (Pubitemid 37377454)
63. Vukicevic, S.; Simic, P.; Borovecki, F.; Grgurevic, L.; Rogic, D.; Orlic, I.; Grasser, W. A.; Thompson, D. D.; Paralkar, V. M. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure Kidney Int. 2006, 70, 1099-1106 (Pubitemid 44344080)
64. Houchen, C. W.; Sturmoski, M. A.; Anant, S.; Breyer, R. M.; Stenson, W. F. Prosurvival and antiapoptotic effects of PGE2 in radiation injury are mediated by EP2 receptor in intestine Am. J. Physiol.: Gastrointest. Liver Physiol. 2003, 284, G490-G498
65. Sheibanie, A. F.; Tadmori, I.; Jing, H.; Vassiliou, E.; Ganea, D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells FASEB J. 2004, 18, 1318-1320 (Pubitemid 39561589)
66. Honda, T.; Segi-Nishida, E.; Miyachi, Y.; Narumiya, S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis J. Exp. Med. 2006, 203, 325-335 (Pubitemid 43290842)
67. Kabashima, K.; Nagamachi, M.; Honda, T.; Nishigori, C.; Miyachi, Y.; Tokura, Y.; Narumiya, S. Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors Lab. Invest. 2007, 87, 49-55 (Pubitemid 44973653)
68. Donnini, S.; Finetti, F.; Solito, R.; Terzuoli, E.; Sacchetti, A.; Morbidelli, L.; Patrignani, P.; Ziche, M. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways FASEB J. 2007, 21, 2418-2430 (Pubitemid 47230672)
69. Kamiyama, M.; Pozzi, A.; Yang, L.; DeBusk, L. M.; Breyer, R. M.; Lin, P. C. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival Oncogene 2006, 25, 7019-7028 (Pubitemid 44722070)
70. Brouxhon, S.; Konger, R. L.; VanBuskirk, J.; Sheu, T. J.; Ryan, J.; Erdle, B.; Almudevar, A.; Breyer, R. M.; Scott, G.; Pentland, A. P. Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness J. Invest. Dermatol. 2007, 127, 439-446 (Pubitemid 46110774)
71. O'Collins, V. E.; Macleod, M. R.; Donnan, G. A.; Horky, L. L.; van der Worp, B. H.; Howells, D. W. 1,026 experimental treatments in acute stroke Ann. Neurol. 2006, 59, 467-477 (Pubitemid 43358067)
72. Liu, D.; Wu, L.; Breyer, R.; Mattson, M. P.; Andreasson, K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia Ann. Neurol. 2005, 57, 758-761 (Pubitemid 40628868)
73. Ahmad, M.; Saleem, S.; Shah, Z.; Maruyama, T.; Narumiya, S.; Dore, S. The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke Exp. Transl. Stroke Med. 2010, 2, 12
74. Serrano, G. E.; Lelutiu, N.; Rojas, A.; Cochi, S.; Shaw, R.; Makinson, C. D.; Wang, D.; FitzGerald, G. A.; Dingledine, R. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus J. Neurosci. 2011, 31, 14850-14860
75. Tani, K.; Naganawa, A.; Ishida, A.; Egashira, H.; Sagawa, K.; Harada, H.; Ogawa, M.; Maruyama, T.; Ohuchida, S.; Nakai, H.; Kondo, K.; Toda, M. Design and synthesis of a highly selective EP2-receptor agonist Bioorg. Med. Chem. Lett. 2001, 11, 2025-2028 (Pubitemid 32709716)
76. Lohse, M. J. Molecular mechanisms of membrane receptor desensitization Biochim. Biophys. Acta 1993, 1179, 171-188 (Pubitemid 23328720)
77. Nishigaki, N.; Negishi, M.; Ichikawa, A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist Mol. Pharmacol. 1996, 50, 1031-1037 (Pubitemid 26347726)
78. Su, Y. F.; Harden, T. K.; Perkins, J. P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process J. Biol. Chem. 1980, 255, 7410-7419 (Pubitemid 11232896)
79. Desai, S.; April, H.; Nwaneshiudu, C.; Ashby, B. Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration Mol. Pharmacol. 2000, 58, 1279-1286
80. Schwenn, O.; Heckmann, B.; Guzy, C.; Miller, P. J. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study BMC Ophthalmol. 2010, 10, 21
81. Susanna, R., Jr.; Giampani, J., Jr.; Borges, A. S.; Vessani, R. M.; Jordao, M. L. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension Ophthalmology 2001, 108, 259-263 (Pubitemid 32115953)
82. Prasanna, G.; Carreiro, S.; Anderson, S.; Gukasyan, H.; Sartnurak, S.; Younis, H.; Gale, D.; Xiang, C.; Wells, P.; Dinh, D.; Almaden, C.; Fortner, J.; Toris, C.; Niesman, M.; Lafontaine, J.; Krauss, A. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma Exp. Eye Res. 2011, 93, 256-264
83. Schachar, R. A.; Raber, S.; Courtney, R.; Zhang, M. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension Curr. Eye Res. 2011, 36, 809-817
84. Schachar, R. A.; Raber, S.; Thomas, K. V.; Benetz, B. A.; Szczotka-Flynn, L. B.; Zhang, M.; Howell, S. J.; Lass, J. H. Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl Cornea 2013, 32, 306-312
85. Jiang, J.; Ganesh, T.; Du, Y.; Quan, Y.; Serrano, G.; Qui, M.; Speigel, I.; Rojas, A.; Lelutiu, N.; Dingledine, R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2 Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 3149-3154
86. Jiang, J.; Quan, Y.; Ganesh, T.; Pouliot, W. A.; Dudek, F. E.; Dingledine, R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 3591-3596
87. Savonenko, A.; Munoz, P.; Melnikova, T.; Wang, Q.; Liang, X.; Breyer, R. M.; Montine, T. J.; Kirkwood, A.; Andreasson, K. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor Exp. Neurol. 2009, 217, 63-73
88. Yang, H.; Zhang, J.; Breyer, R. M.; Chen, C. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor J. Neurochem. 2009, 108, 295-304
89. Hizaki, H.; Segi, E.; Sugimoto, Y.; Hirose, M.; Saji, T.; Ushikubi, F.; Matsuoka, T.; Noda, Y.; Tanaka, T.; Yoshida, N.; Narumiya, S.; Ichikawa, A. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2) Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 10501-10506 (Pubitemid 29422588)
90. Kennedy, C. R.; Zhang, Y.; Brandon, S.; Guan, Y.; Coffee, K.; Funk, C. D.; Magnuson, M. A.; Oates, J. A.; Breyer, M. D.; Breyer, R. M. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor Nature Med. 1999, 5, 217-220 (Pubitemid 29068530)
91. Chun, K. S.; Lao, H. C.; Trempus, C. S.; Okada, M.; Langenbach, R. The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development Carcinogenesis 2009, 30, 1620-1627
92. Fujino, H.; Regan, J. W. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol. Sci. 2003, 24, 335-340 (Pubitemid 37315524)
93. Fujino, H.; Salvi, S.; Regan, J. W. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 Mol. Pharmacol. 2005, 68, 251-259 (Pubitemid 41002965)
94. Jiang, J.; Dingledine, R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Trends. Pharmacol. Sci. 2013, 34, 413-423
95. Regan, J. W. EP2 and EP4 prostanoid receptor signaling Life Sci. 2003, 74, 143-153
96. Bos, J. L. Epac: a new cAMP target and new avenues in cAMP research Nature Rev. Mol. Cell. Biol. 2003, 4, 733-738 (Pubitemid 37082188)
97. de Rooij, J.; Zwartkruis, F. J.; Verheijen, M. H.; Cool, R. H.; Nijman, S. M.; Wittinghofer, A.; Bos, J. L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 1998, 396, 474-477 (Pubitemid 28553318)
98. Duman, R. S.; Malberg, J.; Nakagawa, S.; D'Sa, C. Neuronal plasticity and survival in mood disorders Biol. Psychiatry 2000, 48, 732-739
99. Herold, S.; Jagasia, R.; Merz, K.; Wassmer, K.; Lie, D. C. CREB signalling regulates early survival, neuronal gene expression and morphological development in adult subventricular zone neurogenesis Mol. Cell. Neurosci. 2011, 46, 79-88
100. Ouyang, M.; Zhang, L.; Zhu, J. J.; Schwede, F.; Thomas, S. A. Epac signaling is required for hippocampus-dependent memory retrieval Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11993-11997
101. Shi, G. X.; Rehmann, H.; Andres, D. A. A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation Mol. Cell. Biol. 2006, 26, 9136-9147 (Pubitemid 44851968)
102. Yang, Y.; Shu, X.; Liu, D.; Shang, Y.; Wu, Y.; Pei, L.; Xu, X.; Tian, Q.; Zhang, J.; Qian, K.; Wang, Y. X.; Petralia, R. S.; Tu, W.; Zhu, L. Q.; Wang, J. Z.; Lu, Y. EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation Neuron 2012, 73, 774-788
103. Sugimoto, Y.; Narumiya, S. Prostaglandin E receptors J. Biol. Chem. 2007, 282, 11613-11617 (Pubitemid 47100657)
104. Abramovitz, M.; Adam, M.; Boie, Y.; Carriere, M.; Denis, D.; Godbout, C.; Lamontagne, S.; Rochette, C.; Sawyer, N.; Tremblay, N. M.; Belley, M.; Gallant, M.; Dufresne, C.; Gareau, Y.; Ruel, R.; Juteau, H.; Labelle, M.; Ouimet, N.; Metters, K. M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs Biochim. Biophys. Acta 2000, 1483, 285-293 (Pubitemid 30029060)
105. Nials, A. T.; Vardey, C. J.; Denyer, L. H.; Thomas, M.; Sparrow, S. J.; Shepherd, G. D.; Coleman, R. A. Ah13205, a Selective Prostanoid Ep2-Receptor Agonist Cardiovasc. Drug Rev. 1993, 11, 165-179 (Pubitemid 23338379)
106. Woodward, D. F. EP2-Receptor agonists as agents for lowering intraocular pressure. US 5462968, 31 October 1995.
107. Woodward, D. F.; Pepperl, D. J.; Burkey, T. H.; Regan, J. W. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist Biochem. Pharmacol. 1995, 50, 1731-1733
108. af Forselles, K. J.; Root, J.; Clarke, T.; Davey, D.; Aughton, K.; Dack, K.; Pullen, N. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist Br. J. Pharmacol. 2011, 164, 1847-1856
109. Jiang, J.; Dingledine, R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation J. Pharmacol. Exp. Ther. 2013, 344, 360-367
110. Ganesh, T.; Jiang, J.; Shashidharamurthy, R.; Dingledine, R. Discovery and characterization of carbamothioylacrylamides as EP selective antagonists ACS Med. Chem. Lett. 2013, 4, 616-621
111. Dack, K. N.; Skerratt, S. E.; Yeap, S. K. Azetidine derivatives and their use as prostaglandin E2 antagonists. WO 2008/139287 A1, 20 November 2008.
112. Buchmann, B.; Braeuer, N.; Koppitz, M.; Peters, O.; Ter Laak, A.; Lindenthal, B.; Langer, G.; Wintermantel, T. Thienopyrimidylamines as modulators of the EP2 receptor. WO 2009007422 A1, 15 January 2009.
113. Braeuer, N.; Buchmann, B.; Koppitz, M.; Langer, G.; Lindenthal, B.; Peters, O.; Ter Laak, A.; Wintermantel, T. N -(1-Phthalazin-1-ylpiperidin-4-yl) amides as EP2 receptor modulators. WO2008028689 A1, 13 March 2008.
114. Buchmann, B.; Brauer, N.; Koppititz, M.; Peters, O.; Ter Laak, A.; Lindenthal, B.; Langer, G. Diaminopyrimidines as modulators of the EP2 receptor. WO 2008/152093 A3, 18 December 2008.
115. Koppitz, M.; Lindenthal, B.; Antonious Ter, L.; Wintermantel, T.; Peters, O.; Langer, G.; Bräuer, N.; Buchmann, B. Dérivés de n -(indol-3-ylalkyl)-(hétéro)arylamide comme modulateurs du récepteur WO2010012397 A1, 4 February, 2010.
116. Jiang, J.; Ganesh, T.; Du, Y.; Thepchatri, P.; Quan, Y.; Dingledine, R. J. Preparation of indole and benzimidazole derivatives as prostaglandin receptor EP2 antagonists. WO 2012177618 A1, 27 December 2012
117. Weiss, W. A.; Taylor, S. S.; Shokat, K. M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors Nature Chem. Biol. 2007, 3, 739-744 (Pubitemid 350126879)
118. Iyer, J. P.; Srivastava, P. K.; Dev, R.; Dastidar, S. G.; Ray, A. Prostaglandin E(2) synthase inhibition as a therapeutic target Expert Opin. Ther. Targets 2009, 13, 849-865
119. Okumura, T.; Murata, Y.; Taniguchi, K.; Murase, A.; Nii, A. Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis J. Pharm. Pharmacol. 2008, 60, 723-730 (Pubitemid 351702446)
120. Bunnage, M. E.; Chekler, E. L.; Jones, L. H. Target validation using chemical probes Nature Chem. Biol. 2013, 9, 195-199
121. Simon, G. M.; Niphakis, M. J.; Cravatt, B. F. Determining target engagement in living systems Nature Chem. Biol. 2013, 9, 200-2055
122. Iwamura, R.; Tanaka, M.; Katsube, T.; Shibakawa, N.; Shigetomi, M.; Okanari, E.; Kanda, T.; Tokunaga, Y.; Fujiwara, H. Aminopyridine compound. EP 2520570 A1, 7 November 2012.
123. Hoffmeyer, A.; Boer, R.; Hessmann, M.; Pahl, A.; Dunkern, T.; Hartung, S.; Zitt, C.; Volz, J.; Prachter, C.; Makhija, M.; Jain, H.; Gavade, S.; Prabhu, A.; Tiwari, M.; Keche, A.; Patel, S. Novel ep2 receptor agonists. WO2013164326 A1, 7 November 2013.
124. Old, D. W.; Dinh, D. T. Substituted gama lactams as therapeutic agents. US 2009/0286787, 19 November 2009.
125. Prassanna, G.; Bosworth, C. F.; Lafontaine, J. A. EP2 agonist. US 2008/00455 A1, 21 February 2008.